The following two years witnessed the approval of the radionuclide-linked monoclonal antibodies ibritumomab tiuxetan (Zevalin; anti-CD20) [68] and tositumomab (Bexxar; anti-CD19) [69,70] to treat non-Hodgkin’s lymphoma (2002–3), indicating the beginning of antibody-targeted radiotherapy of cancer [71]. This evidence concerns the gene CD19 and cancer.